ALNYLAM PHARMACEUTICALS, INC. - COM (ALNY)

Historical Portfolio Holders from Q1 2014 to Q1 2024

All holders as of March 31, 2024
Q1 2024
Type / Class
Equity / COM
Shares, excl. options Q1 2024
111 M
Holdings value Q1 2024
$16.5 B
Value change Q1 2024
-$829 M
Grand Portfolio weight change Q1 2024
-0.002%
Number of holders
469
Number of buys Q1 2024
256
Number of sells Q1 2024
-204
Average buys Q1 2024 %
+0.008%
Average sells Q1 2024 %
-0.003%
CUSIP
02043Q107
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q1 111 M $16.5 B -$829 M $149.45 469
2023 Q4 115 M $22 B +$69.3 M $191.41 476
2023 Q3 115 M $20.4 B -$246 M $177.10 440
2023 Q2 116 M $22 B -$422 M $189.94 453
2023 Q1 118 M $23.7 B +$26.4 M $200.32 453
2022 Q4 118 M $28.1 B -$3.1 B $237.65 468
2022 Q3 132 M $26.5 B +$3.4 B $200.16 465
2022 Q2 113 M $16.4 B -$76.9 M $145.85 401
2022 Q1 113 M $18.5 B +$219 M $163.29 416
2021 Q4 111 M $18.8 B +$65 M $169.58 411
2021 Q3 111 M $21 B -$165 M $188.81 390
2021 Q2 112 M $19 B +$508 M $169.52 393
2021 Q1 109 M $15.3 B +$197 M $141.19 380
2020 Q4 107 M $13.9 B -$101 M $129.97 343
2020 Q3 108 M $15.8 B -$457 M $145.60 344
2020 Q2 111 M $16.5 B +$493 M $148.11 360
2020 Q1 108 M $11.7 B +$282 M $108.85 314
2019 Q4 105 M $12.1 B -$227 M $115.17 303
2019 Q3 107 M $8.58 B +$172 M $80.42 271
2019 Q2 106 M $7.68 B +$882 M $72.56 278
2019 Q1 94.7 M $8.85 B +$410 M $93.45 276
2018 Q4 91.8 M $6.69 B +$108 M $72.91 265
2018 Q3 90.5 M $7.92 B -$106 M $87.52 294
2018 Q2 91.5 M $9.01 B +$41.3 M $98.49 301
2018 Q1 91.1 M $10.9 B -$71.7 M $119.10 288
2017 Q4 91.7 M $11.6 B +$606 M $127.05 274
2017 Q3 87.4 M $10.3 B +$78.6 M $117.49 231
2017 Q2 86.9 M $6.93 B +$483 M $79.76 215
2017 Q1 82.2 M $4.21 B +$358 M $51.25 191
2016 Q4 79.5 M $2.98 B -$14.5 M $37.44 197
2016 Q3 77.4 M $5.25 B +$230 M $67.78 251
2016 Q2 74 M $4.11 B +$155 M $55.49 240
2016 Q1 70.2 M $4.41 B +$303 M $62.77 242
2015 Q4 65.9 M $6.21 B +$91.3 M $94.14 254
2015 Q3 63.4 M $5.1 B -$70.7 M $80.36 250
2015 Q2 63 M $7.55 B +$116 M $119.87 271
2015 Q1 64.4 M $6.73 B +$671 M $104.42 233
2014 Q4 58 M $5.62 B -$127 M $97.00 212
2014 Q3 59 M $4.61 B +$102 M $78.10 184
2014 Q2 57.8 M $3.65 B +$130 M $63.17 193
2014 Q1 55.7 M $3.74 B +$17.9 M $67.14 196